FOXY SRL
FOXY reported total assets of 153,611 € at the end of the 2025 financial year (annual accounts filed with the NBB on 31 Aug 2026).
The score of FOXY shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +13 % Total assets -9 %
Accounts of the company itself (not consolidated).
The full file covers 6 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
FOXY's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 31 Aug 2026
- Year ended 31 Dec 2023filed on 30 Aug 2024
- Year ended 31 Dec 2022filed on 31 Jul 2023
- Year ended 31 Dec 2021filed on 19 Jul 2022
- Year ended 31 Dec 2020filed on 30 Jul 2021
FOXY's financial analysis
- Solvency88.4%sector median: 57.9%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of FOXY
FOXY's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0712.621.881
- VAT number
- BE0712621881
- Peppol
- Registered · 0208:0712621881 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 26 Oct 2018
- Registered office
- 6698 Vielsalm
- Latest accounts
- 2025 · filed on 31 Aug 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
FOXY (SRL) has been based in Vielsalm since 2018, active in: research and experimental development on biotechnology. For 2025, it reports a net profit of 3,022 € and equity of 135,799 €; its revenue is not published. Its solvency stands at 88.4%, above the median of its sector (57.9%).
Companies similar to FOXY
Companies in the same business, of comparable size and area, outside its group.
- Sympli Good Food Research and experimental development on natural sciences and engineering Ghent · balance sheet 258,407 €
- Dr. D. FRANCOIS PHOTOMED Research and experimental development on natural sciences and engineering Molenbeek-Saint-Jean · balance sheet 291,936 €
- E-Biom Research and experimental development on natural sciences and engineering Gembloux · balance sheet 372,985 €
- CABINET MEDICAL Geneviève MAHIEU Research and experimental development on natural sciences and engineering Dinant · balance sheet 536,793 €
- Syndesi Therapeutics Research and experimental development on natural sciences and engineering Wavre · balance sheet 607,532 €
- Exo-Harvest Research and experimental development on natural sciences and engineering Charleroi · balance sheet 764,057 €
- Taag Venture Capital Europe Research and experimental development on natural sciences and engineering Antwerp · balance sheet 845,167 €
- Dokter Bart Gordts Research and experimental development on natural sciences and engineering Bruges · balance sheet €1.19m
Frequently asked questions about FOXY
What is the revenue of FOXY?
FOXY files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of FOXY?
In Belgium, the VAT number is the company number prefixed with BE: BE0712621881 for FOXY, if the company is VAT-registered. Its company number (CBE) is 0712.621.881.
Where is the registered office of FOXY?
According to the CBE register, the registered office of FOXY is in 6698 Vielsalm.
What is the equity of FOXY?
At the close of the 2025 financial year, the equity of FOXY amounts to 135,799 €, a solvency of 88.4% of total assets.
Who manages FOXY?
The register lists 1 active mandates at FOXY. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of FOXY
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →